Dosage form using an antagonist to gamma interferon to control MHC-associated autoimmune disease.

摘要

Disease associated with MHC-linked immune response genes are controlled through immunosuppression of the immune response by administering an antagonist of gamma interferon to individuals who are susceptible to or who have an MHC-linked autoimmune disease. More specifically, treatment with antibodies directed against IFN- gamma delays and alleviates the symptoms of MHC-linked autoimmune diseases in mammals.